<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-019071
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050616
<FILING-DATE>20050616
<DATE-OF-FILING-DATE-CHANGE>20050616
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05899370
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v020240_6k.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of June 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                June 16, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td>
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                  Finlay</font></font></div>
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                  Financial Officer and Company
                  Secretary</em></font></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="90%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Korean
                  Patent Granted - Patent granted for electronic stimulation using
                  BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  for &#8220;Smart&#8221; Orthopaedic products</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="10%">&#160;</td>
              <td align="left" valign="top" width="90%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v020240_ex99-1.htm
<TEXT>
<HTML>
  <HEAD>
         <TITLE></TITLE>
  </HEAD>
  <BODY BGCOLOR="#ffffff">
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left">&#160;</DIV>
         <DIV ALIGN="center">
                <TABLE BGCOLOR="#ffffff" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
                  <TR BGCOLOR="#ffffff">
                         <TD WIDTH="50%">&#160;</TD>
                         <TD WIDTH="50%">
                                <IMG SRC="logo.jpg" ALIGN="RIGHT" WIDTH="300" HEIGHT="84" BORDER="0"></TD>
                  </TR>
                  <TR BGCOLOR="#ffffff">
                         <TD WIDTH="50%"><STRONG><FONT SIZE="2">ASX/MEDIA
                                RELEASE</FONT></STRONG></TD>
                         <TD WIDTH="50%">
                                <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                                 ALIGN="right"><STRONG><FONT SIZE="2">16<FONT
                                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
                                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> June
                                  2005</FONT></FONT></STRONG></DIV> </TD>
                  </TR>
                </TABLE> </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&#160;</STRONG></FONT><FONT
                ID="TAB2" STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT
                ID="TAB2" STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&#160;</STRONG></FONT><FONT
                ID="TAB2" STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&#160;</STRONG></FONT><FONT
                ID="TAB2" STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><STRONG>Korean
                Patent Granted</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>Patent
                granted for electronic stimulation using <BR>BioSilicon</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM</STRONG></SUP></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>
                for &#147;Smart&#148; Orthopaedic products</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">
                <DIV>
                  <HR STYLE="COLOR: #000000" ALIGN="center" NOSHADE="NOSHADE" SIZE="2"
                        WIDTH="100%"> </DIV><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
                nanotechnology company pSivida Limited </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>(ASX:PSD,
                NASDAQ:PSDV, Xetra:PSI)</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is
                pleased to announce that it has been granted its first patent in Korea.
                </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This is
                an important patent covering the electronic-based properties of
                BioSilicon&#153; in the stimulation of orthopaedic tissue repair and
                re-engineering where scaffolds are required to support new bone growth. The
                technology also has application for treatment of fractures that do not heal,
                such as &#147;bone non-union&#148;. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                further key application is in management and monitoring of reconstructive
                orthopaedic or implant surgery. pSivida expects this new technology to have
                application in the attachment and integration of smart implants to bone. MEMS
                (micro-electronic etc) components such as strain gauges and accelerometers are
                currently under evaluation as monitors of hip and knee prostheses. Loosening is
                one of the major problems of hip replacement as it leads to both pain and
                further damage to nearby tissues. Current techniques such as radiography are
                not capable of revealing minimal loosening which provides early warning of
                implant-interface failure. Accelerometers attached to bone tissue can detect
                micro-movement between femur and prosthesis. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Korea is
                a key global player in the design and manufacture of micro-components for the
                electronics industry. This technology, based on BioSilicon&#153; provides the
                opportunity to capitalize on Korea&#146;s technology strengths as well as the
                higher margins associated with healthcare products.</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Managing Director Gavin Rezos said, &#147;The global market for products
                enhancing bone growth and fusion is growing rapidly and this trend is likely to
                continue as the requirement for specialist management of a variety of
                orthopedic conditions increases.&#148;</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Korean
                Patent Number 488643 provides protection for silicon implants comprising
                tissue-compatible and biodegradable silicon (BioSilicon&#153;). It further
                provides for electronic-based devices to facilitate the management of
                fractures, fusion and other related challenges in orthopedic
                therapy.</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                pSivida Intellectual Property portfolio consists of 26 patent families, 30
                granted patents and over 80 patent applications. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT><BR></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">
                <DIV ALIGN="left">
                  <TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Released
                                         by:</STRONG></FONT></DIV> </TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%">&#160;</TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%">&#160;</TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
                                         Australia:</STRONG></FONT></DIV> </TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
                                         US:</STRONG></FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Josh
                                         Mann, CFA</FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                                         Jedynak</FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                                         Relations</FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</FONT></DIV>
                                  </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                                         Limited</FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                                         E. Janis &amp; Company, Inc.</FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +
                                         61 8 9226 5099</FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                                         312-943-1100 ext. 12</FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">joshuamann@psivida.com</FONT></DIV>
                                  </TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="26%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</FONT></DIV>
                                  </TD>
                         </TR>
                  </TABLE> </DIV>
                <DIV>&#160;</DIV>
                <DIV>&#160;</DIV>
                <DIV ID="PGBRK"
                 STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <DIV ID="FTR">
                         <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                  <DIV ID="PN" STYLE="PAGE-BREAK-AFTER: always">
                         <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                         <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                                <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                  <DIV ID="HDR">
                         <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                  </DIV>
                <DIV>&#160;</DIV>
                <DIV><FONT
                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
                  TO EDITORS:</STRONG></FONT></DIV> </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
                Limited</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                is a global nanotechnology company committed to the biomedical sector and the
                development of products in healthcare. The company&#146;s focus is the
                development and commercialisation of a modified form of silicon (porosified or
                nano-structured silicon) known as BioSilicon&#153;. As a new and exciting
                biocompatible material, BioSilicon&#153; offers multiple potential applications
                across the high growth healthcare sector, including controlled release drug
                delivery, targeted cancer therapies (including brachytherapy and localized
                chemotherapy), tissue engineering and orthopedics. Potential diagnostics
                applications are being developed through its subsidiary AION Diagnostics
                Limited. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                owns the intellectual property rights to BioSilicon&#153; for use in or on
                humans and animals. The IP portfolio consists of 26 patent families, 30 granted
                patents and over 80 patent applications. The core patent, which recognises
                BioSilicon&#153; as a biomaterial was granted in the UK in 2000 and in the US
                in 2001. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                is listed on NASDAQ (</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
                Australian Stock Exchange (</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
                Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
                PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
                pSivida&#146;s shares also trade in the United Kingdom on the OFEX
                International Market Service (IMS) under the ticker symbol </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company&#146;s strategic partner and largest shareholder is the QinetiQ group,
                the largest science and technology company in Europe. QinetiQ is the former UK
                government Defence Evaluation Research Agency and was instrumental in
                discovering BioSilicon&#153;. pSivida enjoys a strong relationship with QinetiQ
                having access to its cutting edge research and development facilities. For more
                information on QinetiQ visit </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.qinetiq.com</U></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
                information visit </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.psivida.com</U></FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">
                <DIV
                 STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                 ALIGN="justify"><FONT
                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
                  document contains forward-looking statements that involve risks and
                  uncertainties. Although we believe that the expectations reflected in such
                  forward-looking statements are reasonable at this time, we can give no
                  assurance that such expectations will prove to be correct. Given these
                  uncertainties, readers are cautioned not to place undue reliance on such
                  forward-looking statements. Actual results could differ materially from those
                  anticipated in these forward-looking statements due to many important factors
                  including: our failure to develop applications for BioSilicon</FONT><FONT STYLE="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Arial, sans-serif"><SUP>TM</SUP></FONT><FONT
                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> due to
                  regulatory, scientific or other issues. Other reasons are contained in
                  cautionary statements in the Registration Statement on Form 20-F filed with the
                  U.S. Securities and Exchange Commission, including, without limitation, under
                  Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any oral
                  or written forward-looking statements that may be made by or on behalf of
                  pSivida.</FONT></DIV> </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                <DIV ID="PN">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                </DIV> </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`5`$L`P$1``(1`0,1`?_$`,(``0`"`@,!`0$`````
M```````'"`8)`P0%`@$*`0$``@(#`0$`````````````!`4#!@('"`$)$``!
M`P,"`P0$"0H#!0D````!`@,$``4&$0<A$@@Q01,)42(4M&%Q,D(5=18V=H&1
M4G*R([,D%S=BDR71X50F&*(S0V-TE*0U51$``0,"`P,(!0H&`@,!`````0`"
M`Q$$(3$%01(&46%Q@;$R$P>1H<$B<M%"8K(S<Q0T%37PX5*2(U."PD,D5!?_
MV@`,`P$``A$#$0`_`-_E$2B)1$HB41*(E$2B)1%QNNM,-./ONH99925O/.*"
M4H2D:E2E'@`!VDT7PD`5*I_FW6CMQ:KVYAFV-HN^^.=I5R)L.),F1&0H'17B
MS@E38`[RV%@=^E9VP$BIP"U^YXC@8_PX`97\C<O3\E5B<C*?,!R!@W*T;;[=
MX3&4DN1[%<Y[DR<1VA+CC3Q:"B.'S?ATKZ!$,R2H[I]:D&\V.-@Y":GMIV++
M>D7J3O>_UHS&W9A8(MAS3`9C,6\BW\_LDA$CQ4H6A+BEE"TK86E2>=0["#QT
M'R>(,(ID5GX>UI^HL>)&@/816F6-?DY5<.L"V)*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$56MYNK7;7:67]
MF(!?W%W*DK]GMNWN._S,LR#P2B2ML+#/'YNBG/0@UFCA+L<@J/4M?M[,[@]^
M38UN)KS\G;S*"F-E^HKJ=<;NW4)E#VU.VKY2[$V=QMSDE2&M0H)N#QY@"1VA
MSG4#V-MFLGB,C[HJ>558TV^U0[UV[PX_];<S\7\Z]`5VMN]J]OMI[*W8-O\`
M%8.-P`E(?7';UD2%)&@7(D+YG7E?"M1J.YY=FMEL[&"T9N1-#1ZSTG,]:QK?
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M/RD+''0BN[]`UZUURS9=VIJQVPYM<,VN&PC^8P*K98G1NW7*-\BS;/K++NJF
M,*3)L\!QSPKES+/,RCL<(220-./9777$/&G$FF33EFG!UO&31]3BP?.-#R8G
M#!2XK>%X%7XG8L"_KU>O_P`"#_FN5H/_`.\7W_RQ^ERE_I;?ZBN\G/\`+\XM
M-QM\?!_I.V2D*BSUQ),F.=%CUD!]I;:TD@\>50.E7^C^:/$6K-,EGIS9&M-"
M074KR5.%>91Y]/@H6O>17J[,5DVU^QVTVUZ%9#B>WEKQ"_W.*AR\3DEQ^0T5
M("G6Q(DK=6A.NO,$J`/:=:[SL[V:6TCENAX;RP.>W8QU*N%?HFN*U^VTFTM'
MDP,`/+B3ZZKR+KN[<;K=U6?#D0(S"2K_`%JZ.);;4$=JD\ZDI2GT:ZD^@5T7
MJOFW<W]\;/1Q$UHK_EF<&M-,R-XM#1R5JYW](6Q,L`UN])7H"S;&[EEMMBW>
M^9_=;4SCT2%[8BXLK;2RTTV"XX\MP``("!KJ3I78/!AXBD>]^J/B?&YH,?AT
M-2=M6C$$98E0[MT#&U;A3.JKMB^$73J-W)MN].XUI?@[5X:LG8_`;@@H<FNZ
M@JR"X1U`%/B\H+#:^(2$J4/TNQ2[PQNC/:M4@MG:E.+F8$1M^S:=OTW#L_BM
MUJP+8THB41*(E$7$^^Q%9=D27D1X[*2MYYQ02E*1VDD\`*Q3SQP1F21P:UHJ
M230`<I)R7T`DT"B6Y;UXA">4S%3,NO(2"_';"6SIZ%.*03^:NI]2\Z=#M)"R
M(234VL:`WJ+RTGT44YFG2N%30+YMV]N(S'DLRVIMK"SH)#[:5-CXRVI1'YJX
MZ;YUZ)=2!DHDBK\YS06]>X7'U(_3I&C"A4M1I,>8PU*B/HDQGTA;+[:@I"TG
ML((X&NV;>YBN8VRQ.#F.%00:@CE!"@D$&A7!<Y:H%MN$Y"`XJ%&=?2V3H%%M
M!4`3\.E1]3NS:6DLX%3&QSJ<NZ":>I?6-WG`<I4$X]O1<;U>[1:7+%&81<I3
M4=;R7EDI#AT)`*>.E=&</^<]UJ>H06CK9C1(]K20XX;QI7)6<NG-8PNKD%82
MO0*JDHB41*(JL]5_4'=NG7#,=RBT8W$R9^]WH6MV),?<CH;08[KW.%-I42=6
M]-*S0Q>(:*AU_6':9$V1K0ZKJ>HE8/TE=6%]ZC[OFEMO&'P,81BT.')8=ARG
M9!>,EQU!2H.(3IIX?=7*>'PZ*+P_Q`_5'/#F!NZ!ESJ[U1UM"410UO9OGA>P
M>.6S*,X:N;UMNMQ3:XJ;7'1(=#ZVG'@5)6XV`GE:/'6LD<9>:!5NIZI#I\8D
MEK0FF'IY1R+%-C^J7;3J`NM^LV"Q[VS+QV(S-GFZQ&XZ"V\X6T\A0\[J=1Q&
M@K[)"YF:P:7KMOJ+G-BWO=%<0/E*LA6)7*41*(E$2B)1$HB415XW$5;?I:]0
M'[GC5O7)905)DVYU<\%;:3S>TMH/$GL.O"O/GF&ZS_&W$#YK.,N:._`XSXM&
M/BM:<3\TUP%*JUM-[=!`<>O#T+R]A[JXW<[U95*/@R8Z9C2.X+:4$*T^,+'Y
MJJ?(C57,NKBR)]US!(!SM(:?2'#^U9-39[H=U*>,FNEM@V]V!,GQXLV\QY<>
MT1'7$I<DNMQG'EH903JLI;0I1`[`":]#:V"=/N/NG_5*IV2-;(T$T).'.J%)
M^2GXA7Y^K;%;?9#[FO?63_[#=>M?)+]A=]\_ZK%1:E]KU+U=W+D];<(N(85R
MKN#C4,J':$.G5?YTI(JV\VM2?9</R[AH9"V/J=WO2T$=:QV+`Z45V8JOF(O6
MZ';G5OW7&V7I3I*XUXM[LQY`3ZHY5!"D@'MT%>?>$9K2VM"9)[,.>[%L\+IG
MBF`H0US0#G0=:M9PXNP#NHT5HKUBEMRB):[=>T(F6&(6I$BQA/+%ENLE*F4O
MH^>TA0"@V?5)`Y@0-*]CV@\.)H%!1H&`H,M@V#DY`M9N(&S8/Q;6M.7IY5EO
M9P%95E2B+',DS#$L-C1YF79/:L7B2W?`BRKM,9AMNN\I5R(4^M`4K0$Z#NKZ
M&DY+#/<Q0"LC@T'E(':N''LYPK+H\Z7BN76;)8MK(%SDVN='EMQRI)4`ZIE:
MPC4`GUNZOI:1F%QANH9@3&]K@,Z$&GH6!#J*V'5>18$[O8F;L7?!$876-H7-
M>7D\3GY.;7AIS:Z\*Y>$_D*B_K%EO[GC,KTA3(E25I2M"@M"P"E0.H(/80:Q
MJR5>]]KY)::M&/LK+<>6E<N<`=.<(4$MI/P`ZGX]*\^>>FN2Q,@T]AHU]7O^
ME0T:.BM3T@<BM=,B!)<=BCK;G;]&;/3W9<Q<.W6[D2X60"ZXXYJ0D<VH``&I
M.E==>7/E^WBA\KYI"R*.@.[3><YU:`5P``&)H=@Z)=W=>#0`5)7H[A;7JQ&(
MU=K9+=GVHK2U*#P3XK*E<$J)2`"DGAV<#\=6/F#Y7GAV`7=K(Z2&H#MZF\PG
M(U%`6G+(4-,ZKC:WOBG=<*%9;LA,O[#LRUR($LV!]LR(LMQM8::?!&J4J(`T
M6#KH.\5MWDE>:G$Z2UEBD_"N&\UQ:=QKZC`..%'C8-HYRH^I-8:.!&\K"3&X
MSL.6U-Y1#<9<1+*U<J?"*2%ZJU&@TUXZUZ`O(X9()&S4\,M(=4T&Z1[U3L%*
MX[%5-)!%,U&=JQK:>-<8$BTN6TW)EY"X`;N"G%^*#ZO*GQCS'7NTKK32N&^"
MX;J*2T=#XS7`LI,7'>V4;OFIYJ%37S7!:0ZM.C^2SC(<HQK$8`NN59!;L:M:
MG4L)N-TE-1&"ZL$I;\1Y2$\RM#H-=37:H:3DJR:>.%N](X-'*30>M>1CFX^W
MN837K=B><V#)[A'9,A^#:KE%F/(9"@DN*;9<6H)"E`:D::FOI8X9A8X;V"<[
ML<C7'D!![%DMSNELLEOF7:\W"-:;5;VE/3[E,=0PPRVGY2W'7"E*4CO)-?`*
MK,^1L;2YQ``S)R6&6G=S:J_W&)9['N5B]YNT]91!MD&[PY$AY0!44MM-NJ4H
MZ`G@*Y&-PS!4:/4;:1P:R5A)R`<">U8OOAB.R68X_:8.^;MH:QZ+<`_:#>+F
MJU->V^$M(Y'4OL<RO#*O5U/#CI7V-S@?=6#5+>SF8!=4W:X5.[CZ0L:V+P'I
MLPVX9$]L0]87;A/CQT9&+->EW5090I99\1*I4CPQS%6AT&M?9'//>6#2K73X
M7.-H6U(%:.WNC:58^L2NE$-^W^V2Q>].8YD&ZN,6F]LN>%)MLBY,)<9<_1>]
M;1LCO"R*YB)Q%0%7RZM:1/W'RM#N2HPZ>3K5,O,JFPKEL?@,^W2V9\&7ET=V
M)-C.)=:=;5`F%*T+02E0/<0:D6G>/0M8XW<'6<9!J"__`*E09Y7OW]W5^H('
MO2ZR7F059P)]K+T#M6YZH"[*4:9?O+M/@,GV+,]Q<>QN>!S&W3K@PW)`/?X'
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MJ_$_)3\0K\]5VLK;[(?<U[ZR?_8;KUKY)?L+OOG_`%6*BU+[7J70WVF-M8Y:
MH)/[V7<`XE/^%EM?,?SK%0?/2\:S2H(?G/EKU,:ZOK<U<M,;5Y/,L*PYZY(M
MUD@,7B_PDOJ2$1V+,V[&3XSFNHD+XE)YM2HUIG!TETVUMH&7%TP.(HUMJUT8
MWW5PE=FTUJ7;.@*1<!N\31I_Y8^A6EKU"J5*(E$6LOS/@#MAMQJ-?^:E^XO5
M+L^\>A:1QS^6C^+V%4+Z7MM-S]\6\MVDP_,&\+P:4Y%O.XDWUBX^A`6Q'9\-
MM2%/`ZJ/AE24:\5'@D5)F<UGO$8K5-!L[F_#[>-^ZS`N]@Y^C)>=U0]+UVZ;
MKOCC"[^G+,<RIAXVR\^R^R+1(C%'C1W6O$=`(#B5)(5Q&O`:5]AF$@6/7M"=
MI;V^]O-=D:4Q&?*ME'EQ;FWC,MJ<APZ^37+@_MS<68UIDO+4MQ-NFMJ<89*E
M$DAI;;B4^A.B>P"HETS==7E6[<&7SI[5T;C4L.'0<NPJSF]6*3;I$@Y!;V5R
M7+4A;4]A`YE>`H\P<`'$\AUU^`Z]U=!^=/"D^H01W]NTN,((>T8G<..\!]$U
MKS&N0*[#TZ<,):=J@W#LUNF&3G)4`)DQ90"9UO<)"'0GL((^2H:G0UT9P=QK
M><,W!D@HYC^^PY.ID:['#8?2"%97%LV84.?*K18SN/BV6I;B>*F%<%D:VN;R
M@J4#J/#4?57Q'#3C\%>HN&O,;1^(@(MX,E/_`(Y*8GZ)[K^:GO;=T*EFM)(L
M<QRA2+78:B+QLC^[U^^KI7\)54W$?[7=?<R?4*R0]]O2%2K!`/MCBWUE'_:%
M>+N!?WZR^^9]8+8KG[)W0IMZIMO_`.I>PFY&-,QD2;DW:UW2R)4GF4)EN(E-
M!&G8I?AE`_6KW="[=>"M#UVT_%64C`,:5'2,?7DM*/1#FPPGJ/P-Q9"(66%_
M')NO#A<$?N/_`)"&ZL;AM6%=8\+71@U!@.3JM/7EZZ+:=Y@^:G%>G>[6=AU"
M)F>7.'8T(4?7+',94@I'?ZC'*?UJA6S:O6^\777@6)`.+R![3V>M42\MK`$Y
M!O)?,WD,H7#V_LRO9E*2#I.NA+#1!/80RA[C\-2;MU&TY5J?!-KXETZ4Y,'K
M=@/556C\SL`[28#J-?\`FY/N,JL-GWCT*]XY_*Q_'["H:\KD`95N]H`/]*M/
M\>162\R"K>!/M)>@=I5Y^L[<N[[6[`Y7>L?D.0K]>G8]AM5P:7R.1ESU%+CS
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M:EP\Z$)5\WF*AQ`K!;QA[L=BV/BK5'V5L!&:/>:`\@VTYUJ6V`Z:\^ZEKWD3
MEINL>TP+*4.Y%E5W\9XKD2BHH;2$ZK==6$J4=5``<2=2`9TLHC"Z]TC1)]5>
MXAU`,R>4^U>)O[L%E_3EF%KL&07.)<_I.*+EC^06PN-I<0VYR*]58"VG&U`:
M@$]H(-?8I1(%AU?2)=+E#7$&HJ"%N9Z&-WK]NWLJVYE<URZ9)AER=L4Z[/'F
M=ELMMMO1GG5?.7X;H0HGBHIYCQ)JON(PQV"[+X6U)][:5>:N:=TGEVCM5RZP
M+9$HB41*(H*W=W+VUQ&[X=BV79W(Q7(\LDK9QN##F+BK?41RI]H6E*TM-+<`
M0E;@"><Z`_*K7^(N'WZK""R6:-S*D>#(82_#NN-".BHPY<U'?JUO9R-9*6@O
MP%17KYE#>2E5@O<>X0XE]L]\BO\`C/OW=;;Y<<!U#B74I`7KW]H([Z\F<2UT
M?4&7$#+J&Y:[>)G+7ESOZ@\`;W/W@X;5M4/^1M"6EO,I(;WPCS+/*A7:RNHF
MR(SK)D1%I4T5+04A7*L@I&I[-378K/.^*YL7P7=NX2.8YM6$%I)!%:.H0.:K
ME$_32'`M.%57@#0`>@5YX5LIHP/<^WX=CKMJ>M<F=+5*=D(4A2$-Z+2D`%1)
M/S?17<_`GF?:\-Z6ZU?"^20O<X4(#<0`!4U.S^E5UU9.F?O`T%%B=YRI_.,A
MCR[['DNPF@6XUIMFBG$H)UY4%8/%1^4K3\E:MK'%,G%6J,EOF/,0P;'#BX#D
M:75Q=\YU#T4H!GC@$#*-I7E*L;@^-NL-P[H^_D4!MA')"L=SN`>;#?+RI*F6
MTI"=!V)/9Z*]%<$\-/A;'=/=>1AHHR&:;?;NTH"8VAH;3YK3EM`P51<S5JWW
M3S@>U2?79JAI1$HBUE^9[_;#;C\5+]Q>J79]X]"T?CK\M'\7L*AWRN_OENW]
M36SWAZLEYD%7<"?:2]`[5*'FB`?8;:A7>,AF@'XX?^ZN%GWBK#CK["/XBL.\
MK92O:MZDZGE+=A)3W:@S^-<KS8H?`><W_'_LMN]05V*HFRS:+'\@+LRV_P"A
MW1>JBXRG5AQ1X^NUPTU]*=/RUU1Q7Y2:9K!=-;_X)CC5H]QQ^DS97E;3E(*G
M07[X\#B%6?)L2O>)3$Q;M'Y$K),2<T2IEWE[T*X:$>@Z$5YHXFX2U'AR<1W3
M:`]U[<6.I_2>7F-'#D5S#.R85:IVV@SV;=EKQB\O*DR8[)=MDUPZK6VC0*;6
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M>M6\\NK`?LKL0K*9,8,W#<2[/W$/$^LN#%_E8H([AJAQ8_6UK!=.J^G(MCX.
ML_!LM\C%YKU#`>WTK#O,Z_M)@/XN3[C*KE9]X]"B<=?E8_C]A4,^5U]ZMWOJ
MJT_QY%9+S(*MX#^TFZ!VE6)\RHG^@%F&O`YE;M?_`&LRL5IW^I77&WY$?&.Q
MRJYY8"$'<S<QPI!6C&(Z4J[P%34DC\O**S7F05%P*/\`/)\/M"L1YF_]FL)_
M&+/N$RL5GWCT*WXY_*,^/V%0'Y7OW]W5^H('O2ZR7F055P)]K+T#M6XJ\2;+
M;X$FZWY^'#MEM:6_,N$]3;;##:1JM:W'-$I``XDFH(KL78TA8UI<^@`VG8M<
MFZGF.;:8>[-M&T^,KSF<RLH7?'C]'6DJ3P*FSREYX#T\B0>Y1%2F6KCB[!:;
M?\96\!+;=N^>7)ORGU+6KU![N[N;S7+&,IW1L0L43V20C#66;<]`BN1E.)+R
MF%OE2WQS!(*N8@?!4N*-K*@+2-9U&ZOG-?.W=%/=PH*<U<_2ME'EA_VLW$_%
M8]QCU$O.\.A;KP+^6D^/V!;,:B+>$HB410-U#;^8QT_8)(RB]%,Z]SN>-B6-
MI5RNSY@3J!PXI:;X*<7W#A\HI!R11EYHJK5]5CTZ'?=BX]T<I^3E59^E_I_R
M?)\E7U.]0@7=MR,C4F;A^/RDZ-6B,I.K#Q95KX:P@Z,M_P#A)XG]X=4Y9I`!
MN-R5-H>DR2R?C;O&1V+0?FC9AV#9TY;"WX\>4V6I+#<AH]K3J0M)_(H$5`GM
MXIV[DC0YO(0"/05MX)&2PF_X5B*[9=91QR`F0W$>6AU#*4$*2VH@^J!Q!K2M
M>X+T1UI/+^$B#Q&\@AH;B&D@X44F*XDW@-XYJD:?DCXJ\2K8U9?:+%<<O&+N
M3KI9HL^6F>\V'WT!9Y$I00GCPT&IKTOY1\+:7J.CF>ZMV2/\5PJX5P`;0>M4
M]_.]DE&D@44X6^W6F$@*M<&)%;(Y0J*TA`(!TTU0!WUWA9Z7:60I;Q,C^%H;
MV`*L=(7YFJ]&IRXI1$HB41:R_,]_MAMQ^*E^XO5+L^\>A:/QU^6C^+V%0GY8
M$^$QGNZ$!Z6RS.GV2`N#$6M*7'DLR'2Z6TDZJY`H$Z=FM9+P8!5G`KP)I03B
M0.U2%YHE\MWT-M+C(D)5=U7"X75<0<5)C(90P%J]`4M9`].A]%<;,8DJ;QU,
MT1Q1[:D]6"Z?E;0'A'WGNI21&<=L<1M7<7&TS'%C\@6G\]?;PY+'P'&0)G;/
M='UE>K=C+LSQJZQH]LFIA6F<P%QGT,H4LN(.CB"M85V<#P'?7G3S7XMU[0[M
MD=K(&02-JUP:"[>&#FES@>8X4P*[6L8(I6U<*D+FVIW%1.:DV;);J57,O*>@
MS):P`ZA6FK?,=`"D]@]'9V5F\J_,1MVQ]GJ4_P#FWBYCGGO@YMJ<*M.0Y#AD
MOE]:;IWF#!=O>>^6-6-"U"2Q+NDB0TY%9;4E:F@@ZJ<.A/*"G5/PZU*\YM<T
M]VD_A=]KYG/:6@$.+:'%QIEA5O/7I7'3XW^)O4P41[0Q7Y&=VMQD'DAM2'Y*
MAW(\)3?'XU+`KJ3RAM9)N(H7,R8U[G?#NEOUG`*POW`0GG5LLC^[U]^KI7\)
M5>K^(_VNZ^YD^H510]]O2%2K!/OCBWUE'_:%>+N!?WZR^^9]8+8KG[)W0KW5
M[J6LK27YF.!BS[F8;N!'00QFEH7;YYTX>UVI8`.OI4R^@:?X:L+-V!"ZQXXM
M-R=DP^<*=;?Y$>A:^I,_(<XNN.VY]]=RN0C6['+"T>U++/+&B,I^`<P%2J!H
M*T\R27+VM.)P:.K`!?U&8%B4#`L)Q/"K8A*8.+6J);6"D:<WL[24*61Z5J!4
M?A-4[G;QJN]K6W%O$V,9-`'H5`O,Z_M)@/XN3[C*J39]X]"U#CK\K'\?L*AG
MRNOO5N]]56G^/(K)>9!5O`?VDW0.TJR7F1Q'9'3U#?0-40,MMCS_`.JMJ2R/
M^TX*PVI]]7G&C"ZQJ-CAV%4W\M'(K?:]YLKL,QY+,K)\86FU!1`\1V%(;>6V
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M&;AX#G`T`.3<C6G*L$\S/(K#==Q=OK):[K%G7/&[/,1?8,=P+7#7(>;4TAX)
MU"%*2DGE/'30Z<17*S!`*B<<3,?-&UI!+0:CD4_^6'_:S<3\5CW&/6*\[PZ%
M;<"_EI/C]@6S&HBWA*(L<R_*['@V,7W,,EFIM]BQV&[.N<M1'JMM#71()&JE
M'1*1WJ('?7UH)-`L-Q.R"-TCS1K14K65L'AE^ZN]W+AU+;K0BG;_`!>8J%MC
MALC]Y'4J,OF0"E7JJ;85HIPZ:./']%'+4N1PB;N#/:M*TJW?K%R;V<?XVFC&
M[,/DV\I]"VL5#6]I1%Y=\_\`I+Q_Z&1_#557KG[?<?=/^J5SC[XZ0M:.19E8
ML6,&).>=F7N[*2U8\7MS2I=TGNJX);C1&]5J)/?H$CO->).&N$-3XBF\.RB+
M@#[SSA&SXGY=0JX[`K?4=7MM/:#*[WCDT8O=\+<^O+G5H]F<4SFZV(.9S+:Q
MJSMS'71MW:WP[)#J@@A-XN#1T4H)`YH[&B!KRN+<XI'KGR^T*#0M.=9Q3MG<
MV1WB.;W6R4;O,;GW<,3C78,EKLK[B\>))F^&TC!E<:<KW?\`5N'*2K.---,-
MMLLMI99:2$--(`2E*0-``!P`%;LLX%,E]T7U*(E$2B+67YGO]L-N/Q4OW%ZI
M=GWCT+1^.ORT?Q>PJ@72ST_W#?F;G;6/9@_A6885"A7'%KJWSI:4^\ZXA2'E
MM$/-@A(T6V=4_HJ[*E3R[E*C!:EP_I#M0,FX\L>T`M/\8]:S*_=%/5YDV4+.
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M3AC@NK`V>SB6ZA#T!BVM*/KOR'T$)'ZK16H_FJ+8>3W$-R\"2)L3>5SVX=3"
MYWJ7)VH1#(U5B\&P.W85$=#3GMMSE@>W7!2>4D#L0A/'E2#\/'OKT5P/P):\
M,0$,._,^F^\BE?HM&QO74G$[*5%S<NF/-R+*KS&=F6BZPV`%/RX;[+*2=`5N
M-J2G4]W$UM.L6S[FQGAC[SXWM'2YI`]:PQG=<">55IQ;:K,K5D=BN4R''1%@
M3&7I*DR$*(0A6I(`[:\V<+^5>NV&JVUS-&P,CD:YU'M.`-3@KB>^B>P@'$A6
MHKU(J15+ZRMCKYOKM0Q8\1CQ9&86&\1KG8T2G4L)6G13$EKQE<$ZMN%7'M*1
M6:"3<=4Y*@XDTM^H6NY&/?!!'8?XYE1;IWZ%]XL3WFP7+-QK1:X6*XM--UDK
M8N#,MQ<B,A2XJ`TCB?WW(2>X"I,MRUS2`M5T7A6Z@NV23`;K37,'$9>M;G:@
M+LE4LZWME,_WPV_Q/'MO8$2?<[3D*;C-;ERFXB4L"*^UJ%.<">98X5(MY`PD
ME:SQ1I<VH0,9$*D.KG380HXZ&NG#=38N_;A3]Q+7!M\;(H$!BUJB36I94N.Z
M\IP*#?R=`L=M<KB5KP**'PMHMQI[Y#,`-X"F(.55=3=O;6S;O;=Y3MW?7%1X
M621"RW.0D+<BR&U!V/(0E7`EMQ"5::\=-.^H['EIJ%LU_9,O('0OR</0=AZB
MM(5PZ%.J7$<H0,8L+5T7;Y/-9\OLMWC1!JGBAY!>>8?9.GI3P[`35B+F,C%=
M7/X4U*"7_&*T.#@X#M((4X7[H`W;N^W5UR7)<E.>[X765!1;X4JZ.+C0(*5D
MR0[-E'5]TIT``T0GCR\Q/-6(7+0[#`*WEX1N'VY?([?F-*8Y#I.9_C%3=T.=
M->Z^QF5YY=MQ+7`M\*_6F)$MJXDYJ6I3K3ZW%A26^*0$D<36.XE:\"BL^%M$
MN=/D>9@`",,05F76ITIWK?J+8,NP63&;SG%HSD%5KFN>"S<8*U^*EM+Q!#;K
M:RHIYO5(402.!KY;S;F!R4CB;0':BUKXC[[<*':/E"U\X9T=]9=EN$J%CEMF
MX$U<2EBZ7-C(V(<=QOCH7?8I*W'$IU/8A1^"I3IXSGBM/M>&]6C<0P%@.9W@
M!ZBI"W`\N'=&V6O%7L+O,7.<EGIENYY(E2408[+Y4VI@12_^\=!U7S+6=21K
MHG72N#+MNW!3;S@NX:UIC=ON-=[&@YJ5ZU=SH>V4W$V/PG-,?W$MD2W3;M?4
M7"VF)+;EI6U[*VTKF+?R2%([#4>XD#R"%L_"^ESZ?"]DPH2ZN8.Q7;J.MG2B
M+7OY@9R?(<4VEVVQ]QQBU[DYO%L]\GMZ^&ES5*(K+JAPT4XX5Z'M+8]%2;:@
M)/(%J7%OB2110LR>\`^P>WJ5X,*Q"R8!B6/87CD81+)C4%F!;V0`"4-)T*UZ
M::K6K52CWJ)-1W.+C4K9K:W9;QMC8*-:*!917Q9U&VY&[^VVTEJ5=]P<N@8Z
MQR%4:(\YSRY&GS8\5OF==/=ZJ3IWZ5S8PNR4*\U"WLV[TSPWM/0,RJ<2M_=X
M^H2+-8V7L*-I-J'`MBY[VY@T"^\TK5*Q:H`)2M9&H!U7Q[2VJH6KW-C86KWW
MSVMBH0[>-`01B.4UY!B=BI(=1OM5=NV3"QG^QPQ_XC+MYRU=#%L8PK;)N4,%
M9EW/*+DV6\CW6OBO'OMPYAZZ6G%:^RLGN0WIPTUKS#Q?YLF6']/T5GX>V`IO
M-&XYP^B!W`>7OGZ.(6XZ5P[%:.\60E\IS<[%WI]@]:GS;3<JPXK9)%IO#<H.
MJEN26WV4!Q*DN)2-#ZP((*?14GRT\R-.T'3W6EX'[WB%X<T!P(<`,<00<%8W
MEF^5^\VF2LQ`FL7*##N$;F,><PW(8*AHKD<2%)U'<=#7I2PO8[VWCN(Z[DC0
MYM<#1PJ*]15.YI:2#L7;J6N*41*(E$6LOS/?[8;<?BI?N+U2[/O'H6C\=?EH
M_B]A4.^5W]\MV_J:V>\/5DO,@J[@3[27H':MRU0%V2E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:P,,ZVL0PN\YOM5U`6"X1+EB^6W4
MP+V(?MK3C)N+LJ,9#!_>(6US)+:TI4"D)4-#VRW6Y<`6K2+?B:&![X+MI!:]
MU#2OSB1AS;,U(.2^8_L#:6'!C\?(LPN!T$:+$@>RMK4>XN2UMD?D0?BKB+5^
MU2YN,K)H]S><>84[?D4<'>/K:ZA$F+M1MJSLWB$\>IE]Y"D2/!5PYVY$MM/-
MJ#J"Q&41W*KEX<;,S4J'^HZOJ.$$?A,/SC\I_P"K5*.UG0CAMCO#><;SY#,W
MISYQ8?D/W93B[:AWM&K+RG')'*>PO*Y?_+%<'W!.#<`IUCPM%&[Q;EQE?S]W
M^?7Z%>D0((88BB$P(T5(1&CAM/(VE(Y4I0G31(`&@`J#-;QS4\1H=3E`/:MJ
M;[HH,%^?1UO_`.!C_P"4C_96'].M?]3/[1\BY;[N5/HZW_\``Q_\I'^RGZ=:
M_P"IG]H^1-]W*NTE*4)2A"0E*1HE(&@`'8`*EM:&@`"@"XKZKZB41*(E$76E
M0H<U*438C,M"#S(0\VEP`]FH"@:+BYH=F*KXBVZWP5+5"@1X:G``XIAI#94!
MV`\H&M*HUC6Y`!=RBY)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$57=Y_P#I'^T,?^MWV$^U?@CD^FO9_I#P=!R>)I^]Y=-.7GX?HUF9
MXE/=K14>I?IF_P#^SX>_STWJ=JY=J/\`I&]K9_I'_3GZ7\7^6^B_8/I'G_P<
MW\Q\6E'^)\ZJ^V'Z9O?^OX>]S4WOE5G:PJ[2B)1$HB41*(E$2B)1$HB41*(E
G$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
